In this episode, TRC Healthcare Associate Editor and Clinical Pharmacist Vickie Danaher, PharmD discusses how semaglutide became the first FDA-approved oral GLP-1 agonist for obesity
The market dynamics are further influenced by the introduction of oral formulations
Most studies have been conducted in animal models or small human trials with high risk of bias, and findings often lack replication in larger, well-controlled clinical studies
Monitoring Blood Sugar Levels During the Restart Period Careful glucose monitoring is essential when restarting Ozempic after surgery, as the perioperative period and medication interruption can significantly affect blood sugar control
Enhanced Muscle Mass: The combination of Tesamorelin Ipamorelin peptide stack could significantly enhance muscle mass by stimulating growth hormone (GH) release and increasing insulin-like growth factor 1 (IGF-1) levels
High rates of attrition (12%) were observed in Altimmunes trials, and 5% of patients on semaglutide discontinued treatment due to nausea, vomiting or diarrhea (with 25-44% of patients reporting symptoms)